In vitro anti-Leishmania activity of tetracyclic iridoids from Morinda lucida, benth. Issue 1 (December 2016)

• Record Type: Journal Article
• Authors: Amoa-Bosompem, Michael; Ohashi, Mitsuko; Mosore, Mba-Tihssommah; Agyapong, Jeffrey; Tung, Nguyen; Kwofie, Kofi; Ayertey, Frederick; Owusu, Kofi; Tuffour, Isaac; Atchoglo, Philip; Djameh, Georgina; Azerigyik, Faustus; Botchie, Senyo; Anyan, William; Appiah-Opong, Regina; Uto, Takuhiro; Morinaga, Osamu; Appiah, Alfred.; Ayi, Irene; Shoyama, Yukihiro; Boakye, Daniel; Ohta, Nobuo
• Is Part Of: Tropical medicine and health. Volume 44:Issue 1(2016)
• Page Start: 1
• Page End: 5
• Publication Date: 2016-12
• Subjects: Leishmania -- Leishmaniasis -- Cytokinesis -- Morphology -- Proliferation -- Microscopy -- Chemotherapy; 616.9883
• DOI: 10.1186/s41182-016-0026-5
• Languages: English
• ISSNs: 1349-4147

Abstract

Abstract Leishmaniasis is an infectious disease transmitted by the sand fly. It is caused by over 20 different species ofLeishmania and has affected over 14 million people worldwide. One of the main forms of control of leishmaniasis is chemotherapy, but this is limited by the high cost and/or toxicity of available drugs. We previously found three novel compounds with an iridoid tetracyclic skeleton to have activity against trypanosome parasites. In this study, we determined the activity of the three anti-trypanosome compounds againstLeishmania using field strain, 010, and the lab strainLeishmania hertigi . The minimum inhibitory concentration (MIC) of the compounds against 010 was determined by microscopy while the IC50 of compounds againstL. hertigi was determined by fluorescence-activated cell sorting with Guava viacount analysis. We found two of the three compounds, molucidin andML-F52, to have anti-Leishmania activity against both strains. The fluor-microscope observation with DAPI stain revealed that both Molucidin and ML-F52 induced abnormal parasites with two sets of nucleus and kinetoplast in a cell, suggesting that compounds might inhibit cytokinesis inLeishmania parasites. Molucidin and ML-F52 might be good lead compounds for the development of new anti-Leishmania chemotherapy.